Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

J. Matthew Singleton Biography and Net Worth

Director of Viking Therapeutics

In October 2011, Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir (formerly CitationShares LLC), a privately-held jet services company wholly-owned by Textron Inc., a public industrial conglomerate. He had served in this position since 2000. Mr. Singleton has extensive financial, accounting and transactional experience, including through his role as Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking company, for 20 years, at Arthur Andersen & Co., a public accounting firm, including as Partner-in-Charge of the Metro New York Audit and Business Advisory Practice, and as a Practice Fellow at the Financial Accounting Standards Board, a private organization responsible for establishing financial accounting reporting standards. From 2003 until 2014, Mr. Singleton served as a director of Cubist Pharmaceuticals Inc., and as Audit Committee Chair beginning in 2004. Mr. Singleton previously served as an independent director of Salomon Reinvestment Company Inc., a privately-held investment services company. Mr. Singleton received an AB in Economics from Princeton University and his MBA from New York University with a focus in Accounting.

What is J. Matthew Singleton's net worth?: The estimated net worth of J. Matthew Singleton is at least $489,345.00 as of September 20th, 2024. Mr. Singleton owns 9,500 shares of Viking Therapeutics stock worth more than $489,345 as of December 3rd. This net worth evaluation does not reflect any other investments that Mr. Singleton may own. Learn More about J. Matthew Singleton's net worth.
How do I contact J. Matthew Singleton?: The corporate mailing address for Mr. Singleton and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on J. Matthew Singleton's contact information.
Has J. Matthew Singleton been buying or selling shares of Viking Therapeutics?: J. Matthew Singleton has not been actively trading shares of Viking Therapeutics during the last ninety days. Most recently, J Matthew Singleton sold 10,300 shares of the business's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $69.50, for a transaction totalling $715,850.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company's stock, valued at $660,250. Learn More on J. Matthew Singleton's trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 1,383,618 shares worth more than $81,779,033.02. The most recent insider tranaction occured on November, 8th when Director Lawson Macartney sold 2,000 shares worth more than $137,340.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 11/8/2024.

J. Matthew Singleton Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/20/2024	Sell	10,300	$69.50	$715,850.00	9,500
8/21/2024	Sell	5,700	$69.72	$397,404.00	9,500
8/19/2024	Sell	16,000	$62.22	$995,520.00	9,500
8/14/2024	Sell	20,786	$57.53	$1,195,818.58	9,500
5/31/2018	Buy	9,500	$9.82	$93,290.00	9,500

J. Matthew Singleton Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $50.78

$49.90

$51.50

50 Day Range

MA: $62.42

$49.11

$78.03

2 Week Range

Now: $50.78

$14.02

$99.41

Volume

1,406,884 shs

Average Volume

4,489,817 shs

Market Capitalization

$5.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89